Phase 1 CAR T-Cell Trial for Kappa Myeloma Antigen in Relapsed/Refractory Multiple Myeloma
Summary
The National Institutes of Health has registered a Phase 1 clinical trial (NCT07541391) evaluating the safety and efficacy of escalating doses of autologous PMCC-COE-KMA CAR T-cells in patients with relapsed/refractory multiple myeloma expressing the kappa myeloma antigen. The trial will assess CAR T-cell therapy produced using lentiviral vectors following lymphodepleting conditioning chemotherapy. This registry entry documents an investigational Phase 1 study and does not represent approval of the therapy or establishment of new regulatory obligations.
What changed
This document adds a new clinical trial registration entry to ClinicalTrials.gov for a Phase 1 study of CAR T-cell therapy targeting the kappa myeloma antigen in patients with relapsed or refractory multiple myeloma. The registry entry provides study metadata including the phase classification, intervention type, and condition studied.
For compliance and regulatory affairs teams monitoring clinical development activity, this registry entry indicates that an investigational CAR T-cell product is entering early-phase clinical evaluation. Sponsors and investigators conducting similar cellular therapy programs for multiple myeloma may wish to monitor this trial for competitive intelligence purposes, but the registration does not impose any new compliance obligations on external parties.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Autologous Chimeric Antigen Receptor (CAR) T-cells Targeting the Kappa Myeloma Antigen (KMA) in Kappa Restricted Multiple Myeloma Patients With Relapsed/Refractory Disease
Phase 1 NCT07541391 Kind: PHASE1 Apr 21, 2026
Abstract
The study proposed here intends to evaluate the safety and efficacy of escalating doses of autologous PMCC-COE-KMA CAR T-cells administered to patients with relapsed/refractory multiple myeloma that expresses the KMA. The PMCC-COE-KMA CAR T-cells will be produced using LV and administered to patients after lymphodepleting conditioning chemotherapy. Considering the poor prognosis of myeloma patients who have relapsed after ≥ 2 lines of therapy, combined with evidence of PMCC-COE-KMA CAR T-cell specificity, as well as the efficacy and manageable toxicity of PMCC-COE-KMA, investigators believe the potential benefits outweigh the risks of this trial.
Conditions: Relapsed/Refractory Multiple Myeloma
Interventions: PMCC-COE-KMA
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.